NMPA orders active medical device use period clarity



China’s National Medical Products Administration (NMPA) released a set of guidelines in relation to active medical devices. The guidance calls for research into such devices to take into account the product lifespan, requires medical device applicants/registrants to include the active medical device use period within filings, and also provides guidance for reviewers.

The active medical device lifespan is referred to as an applicable range where the medical device applicants/registrants ensure the products’ safety and efficacy via risk management. The medical device applicants are required to specify the use period of the product within filings, alongside relevant verification information, according to China’s medical device laws and regulations on product use and validity period.

Reference:

Related news
China’s National Medical Products Administration (NMPA) released a draft proposal in relation to drug filing-related on-site inspections, requesting public feedback until June 3, 2019.
China is set to double down on medical device manufacturer monitoring via a new information platform.
The National Medical Products Administration (NMPA) released a notification relating to clinical trial institution qualifications, indicating that the Hong Kong Sanatorium and Hospital is the latest medical institution qualified to carry out clinical trials to enable drug registration filings by the NMPA.
The National Medical Products Administration (NMPA) issued two drug information standards on April 28, 2019: “Guidance on the construction of a drug information and traceability system” and “Requirements for drug traceability coding”.
China announced several red tape-cutting changes to pharmaceutical regulations.
Recent news
Argentina-based Laboratorios Bagó this week opened a new injectable drugs production facitlity in Buenos Aires.
Brazil’s health technology company WW8 last week launched its platform Athimos (www.athimos.com), a medical communications and patient records system.
Brazil’s Ministry of Health has requested the Oswaldo Cruz Foundation (Fiocruz) to supply the Unified Health System (SUS) with immunosuppressant tacrolimus for kidney and liver transplant patients.
Cuba’s state-run biopharmaceutical group BioCubaFarma this week presented its products to Chile’s biotechnology and pharmaceutical industry.
Beijing-headquartered Contract Research Organization (CRO) Joinn Laboratories (China) Co., Ltd (603127.SH) has entered into an equity purchase agreement with U.S.-based pre-clinical CRO Biomedical Research Models Inc​.
The National Health Commission released its annual statistical round-up of China’s national health system during 2018.
Shanghai-based Allist Pharmaceuticals Inc., raised RMB 1.18 billion (USD 162 million) via a Series A financing round led by Shenzhen Shiyu Investment Management Co., Ltd​.